BioMedNewsBreaks Archive - Page 197 of 234

WednesdayFeb 10, 2021 12:38 pm

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Configures MiQLab(TM) to Detect Variants of COVID-19 Pathogen

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has successfully configured a MiQLab(TM) system to detect mutant sequences unique to the United Kingdom (“UK, B.1.1.7”) 1 and South African (“SA, B.1.351”) 2 variants of SARS-CoV-2, the pathogen that causes COVID-19. “Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab,” said Dr. Jack Regan, LexaGene’s CEO and founder. “After just two full work days of having these reagents in-house,…

WednesdayFeb 10, 2021 9:35 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical trial in Q2 2021. The clinical trial will evaluate PH94B (“PH94B”), a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). With an estimated 20 million people in the United States suffering from SAD, it is one of the most prevalent mental health conditions in the…

TuesdayFeb 09, 2021 12:03 pm

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Further Lab Results Validating Natural Biopesticide Control of Banana Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, as released additional lab results confirming its mustard-derived natural biopesticide ability to obtain 100% control of on the disease Fusarium wilt TR4. A banana disease often referred to as the Panama disease, Fusarium wilt TR4 is destroying the $25 billion global banana industry. These most-recent results were conducted by a third party and validate earlier test results that confirm the efficacy of MustGrow’s safe and effective natural, plant-based biopesticide. The test results confirm 100% control achieved at economic…

TuesdayFeb 09, 2021 10:25 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s novel gene therapy clinical development programs in cancer and diabetes. More specifically, CAB members will provide invaluable guidance and advise as Genprex advances its REQORSA(TM) (“REQORSA”) immunogene therapy program and its preclinical diabetes gene therapy program. Board members include the following: Michael Morse, MD, MHS,…

TuesdayFeb 09, 2021 9:47 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Collaboration for Planned Phase 2 Clinical Trial of FW-1022

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced its entry into an agreement with PPD Inc. (NASDAQ: PPD ), a leading global contract research organization (“CRO”), for its planned Phase 2 clinical trial evaluating a proprietary formulation of micronized niclosamide as a treatment for COVID-19-associated GI infections. Under the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022. Licensed in January from FirstWave Bio Inc., the goal of AzurRx’s FW-1022 clinical program is…

MondayFeb 08, 2021 11:46 am

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL(TM). The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. “With our Helomics division’s deep experience in clinical profiling of patient tumor drug response, plus our unique PeDAL platform, we have all the components to perform in-house drug repositioning and even full drug discovery. We are…

MondayFeb 08, 2021 11:09 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in BIO CEO & Investor Digital Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that its CEO James Sapirstein will present at the virtual BIO CEO & Investor Digital Conference. The conference is slated for Feb. 16–18, 2021. During the online event, all registered attendees will be able to access Sapirstein’s presentation on demand. The presentation will include an overview of AzurRx BioPharma, including its business and clinical-development programs; Sapirstein will also talk about goals and accomplishments the company is working toward in 2021. Following the presentation, Sapirstein and other members of the AzurRx management team will be…

FridayFeb 05, 2021 3:25 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Delivers Essential Solutions During Ongoing Pandemic

United Medical Equipment (“UME,” “UMEBSNI”) continues to move quickly to address the unique testing needs created by the ongoing global pandemic. UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits as part of its efforts to provide essential services during the epidemic. The company’s COVID-19 IgG/IgM Rapid Test Cassette detects coronavirus antibodies that appear in the bloodstream of individuals infected with the virus within 10 minutes. In addition, the test can also indicate whether a person has protection against the coronavirus. A recent article discussing this reads, “Other features of the test include the following: FDA Emergency…

FridayFeb 05, 2021 10:11 am

BioMedNewsBreaks – Intec Pharma Ltd. (NASDAQ: NTEC) Featured by M-Vest

Intec Pharma (NASDAQ: NTEC), a clinical-stage biopharmaceutical company, was recently highlighted as a featured company by M-Vest. The business description reads, “Intec’s strategy is to leverage its proprietary delivery technology to improve the properties of known/approved compounds. Intec also plans to work in collaboration with biotechnology and pharmaceutical companies to develop novel delivery systems for their proprietary drugs, including existing compounds undergoing lifecycle management.” For more details, visit https://ibn.fm/WUpyI About Intec Pharma Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(R) platform technology. The company's Accordion Pill is an oral drug…

FridayFeb 05, 2021 9:21 am

BioMedNewsBreaks – Adial Pharmaceuticals Inc (NASDAQ: ADIL) Featured by M-Vest

Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, was recently highlighted as a featured company by M-Vest. The update reads, “Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04. Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Configures MiQLab(TM) to Detect Variants of COVID-19 Pathogen

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Further Lab Results Validating Natural Biopesticide Control of Banana Disease

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Collaboration for Planned Phase 2 Clinical Trial of FW-1022

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in BIO CEO & Investor Digital Conference

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Delivers Essential Solutions During Ongoing Pandemic

BioMedNewsBreaks – Intec Pharma Ltd. (NASDAQ: NTEC) Featured by M-Vest

BioMedNewsBreaks – Adial Pharmaceuticals Inc (NASDAQ: ADIL) Featured by M-Vest

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search